ZA988886B - Formulation for treatment of osteoporosis - Google Patents

Formulation for treatment of osteoporosis

Info

Publication number
ZA988886B
ZA988886B ZA988886A ZA988886A ZA988886B ZA 988886 B ZA988886 B ZA 988886B ZA 988886 A ZA988886 A ZA 988886A ZA 988886 A ZA988886 A ZA 988886A ZA 988886 B ZA988886 B ZA 988886B
Authority
ZA
South Africa
Prior art keywords
osteoporosis
formulation
treatment
Prior art date
Application number
ZA988886A
Other languages
English (en)
Inventor
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA988886B publication Critical patent/ZA988886B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA988886A 1997-10-10 1998-09-29 Formulation for treatment of osteoporosis ZA988886B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA988886B true ZA988886B (en) 1999-04-12

Family

ID=20408561

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988886A ZA988886B (en) 1997-10-10 1998-09-29 Formulation for treatment of osteoporosis

Country Status (14)

Country Link
US (1) US6372728B1 (de)
EP (2) EP1310259A3 (de)
JP (1) JP2001519398A (de)
AR (1) AR015946A1 (de)
AT (1) ATE240107T1 (de)
AU (1) AU9469198A (de)
DE (1) DE69814656T2 (de)
DK (1) DK1021194T3 (de)
ES (1) ES2200378T3 (de)
PT (1) PT1021194E (de)
SA (1) SA98190775A (de)
SE (1) SE9703691D0 (de)
WO (1) WO1999018972A1 (de)
ZA (1) ZA988886B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038693A1 (en) * 1998-12-25 2000-07-06 Toray Industries, Inc. Interleukin-6 production inhibitors
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
WO2003003999A2 (en) * 2001-07-02 2003-01-16 Elan Corporation, Plc. Delivery of a bioactive material
JP4546704B2 (ja) * 2002-02-14 2010-09-15 救急薬品工業株式会社 経皮投与製剤
CN1633300A (zh) 2002-02-14 2005-06-29 山之内制药株式会社 透皮制剂
KR20140021045A (ko) 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ITMI20032175A1 (it) * 2003-11-11 2005-05-12 Tiberio Bruzzese Formulazioni farmaceutiche di bisfosfonati destinate
US20050182028A1 (en) * 2004-02-13 2005-08-18 Chen Chih-Ming J. Pharmaceutical formulation for oral delivery of bisphosphates
BRPI0511530A (pt) * 2004-05-24 2008-01-02 Procter & Gamble formas de dosagem de bisfosfonatos
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (de) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonatverbindungen und -verfahren für knochenschwundkrankheiten, krebs, knochenschmerzen, immunstörungen und infektionskrankheiten
US20080317850A1 (en) * 2005-04-08 2008-12-25 Ernest Alan Hewitt Buccal Delivery System
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
WO2007117706A2 (en) * 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2007132714A1 (ja) * 2006-05-16 2007-11-22 The Nisshin Oillio Group, Ltd. 骨密度増加剤
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
CN102046192B (zh) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
EP0416689B1 (de) * 1989-09-06 1995-11-29 Merck & Co. Inc. Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
EP0684834A4 (de) 1993-02-17 1996-09-25 Smithkline Beecham Corp Mikroemulsionen, die therapeutische peptide enthalten.
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
EP1310259A2 (de) 2003-05-14
SA98190775A (ar) 2005-12-03
DE69814656D1 (de) 2003-06-18
PT1021194E (pt) 2003-09-30
DE69814656T2 (de) 2004-03-25
AU9469198A (en) 1999-05-03
EP1021194B1 (de) 2003-05-14
SE9703691D0 (sv) 1997-10-10
AR015946A1 (es) 2001-05-30
ATE240107T1 (de) 2003-05-15
JP2001519398A (ja) 2001-10-23
EP1021194A1 (de) 2000-07-26
DK1021194T3 (da) 2003-09-01
EP1310259A3 (de) 2003-05-21
ES2200378T3 (es) 2004-03-01
WO1999018972A1 (en) 1999-04-22
US6372728B1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
AU9469198A (en) New improved formulation for treatment of osteoporosis
PL328831A1 (en) Combined treatment of osteoporosis
GB9407135D0 (en) Treatment of osteoporosis
HUP0002183A3 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
ZA95556B (en) Combination treatment for osteoporosis
EP1077704A4 (de) Kombinationstherapie zur behandlung der depression
AU6245898A (en) Injectable formulations for treatment of osteoporotic bone
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AUPO907697A0 (en) Chemical supplementation of bone
GB9725114D0 (en) Treatment of pruritus
GB2326116B (en) Treatment of chocolate
EP1007041A4 (de) Zusammensetzung zur behandlung von schmerzen
IL120955A0 (en) Treatment of osteoporosis
SI1021194T1 (en) New improved formulation for treatment of osteoporosis
PL320564A1 (en) Therapeutic set for treating osteoporosis
GB9717451D0 (en) Apparatus for treatment of surfaces
HUP0203741A3 (en) Treatment of osteoporosis
SI1175904T1 (sl) Alendronat za rabo pri zdravljenju osteoporoze
IL120254A0 (en) Composition for treatment of acne
ZA968383B (en) Composition for treatment of osteoporosis.
GB9721978D0 (en) Treatment of depression
GB2322623B (en) Treatment of liquid
HUP9902723A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating migraine pain
IL121227A0 (en) Composition for the treatment of seborrhea
GB9708700D0 (en) Treatment of depression